1
|
Ronot M. Illuminating the shades of hyper- to isointense lesions in hepatobiliary phase imaging. Eur Radiol 2024:10.1007/s00330-024-10894-2. [PMID: 38981895 DOI: 10.1007/s00330-024-10894-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Revised: 04/23/2024] [Accepted: 05/03/2024] [Indexed: 07/11/2024]
Affiliation(s)
- Maxime Ronot
- Department of Radiology, Beaujon Hospital APHP.Nord, Clichy, France.
- Université Paris Cité, CRI INSERM URM 1149, Paris, France.
| |
Collapse
|
2
|
Aziz H, Underwood PW, Gosse MD, Afyouni S, Kamel I, Pawlik TM. Hepatic adenoma: evolution of a more individualized treatment approach. J Gastrointest Surg 2024; 28:975-982. [PMID: 38521190 DOI: 10.1016/j.gassur.2024.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 03/07/2024] [Accepted: 03/09/2024] [Indexed: 03/25/2024]
Abstract
BACKGROUND Hepatic adenomas (HAs) are benign, solid liver lesions, which carry a risk of hemorrhage and malignant transformation. This review article highlights the advances in the diagnosis and management of HAs. METHODS A comprehensive review was performed using MEDLINE/PubMed and Web of Science databases with a search period ending on September 30, 2023. Using PubMed, the terms "hepatocellular," "hepatic," and "adenoma" were searched. RESULTS HA has been classified into at least 8 subtypes based on molecular pathology, each exhibiting unique histopathologic features, clinical considerations, and risk of malignant transformation. The most common subtype is inflammatory HA, followed by hepatocyte nuclear factor 1α-inactivated HA, β-catenin exon 3-mutated HA (βex3-HA), β-catenin exon 7- or 8-mutated HA, sonic hedgehog HA, and unclassified HA. Magnetic resonance imaging is the best imaging method for diagnosis and can distinguish among HA subtypes based on fat and telangiectasia pathologic characteristics. The risk of malignant transformation varies among molecular subtypes, ranging from <1% to approximately 50%. Up to 42% of HAs present with spontaneous intratumoral hemorrhage and peritoneal hemorrhage. In general, only 15% to 20% of patients require surgery. HA larger than 5 cm are more likely to be complicated by bleeding and malignant transformation, regardless of subtype, and should generally be resected. In particular, βex3-HA carries a high risk of malignant transformation and can be considered a true precancerous lesion. CONCLUSION The management of HAs is based on a multidisciplinary approach. Clinical decision-making should integrate information on gender, tumor size, and HA subtyping. In the future, patients with HA will benefit from novel medical therapies tailored to the individual molecular subtypes.
Collapse
Affiliation(s)
- Hassan Aziz
- Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
| | - Patrick W Underwood
- Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
| | - Matthew D Gosse
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
| | - Shadi Afyouni
- Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland, United States
| | - Ihab Kamel
- Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland, United States
| | - Timothy M Pawlik
- Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States.
| |
Collapse
|
3
|
Yang G, Su F, Han BX, Su HX, Guo CH, Yu SH, Guan QL, Hou XM. HNF1A induces glioblastoma by upregulating EPS8 and activating PI3K/AKT signaling pathway. Biochem Pharmacol 2024; 223:116133. [PMID: 38494066 DOI: 10.1016/j.bcp.2024.116133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/04/2024] [Accepted: 03/14/2024] [Indexed: 03/19/2024]
Abstract
Despite the exact biological role of HNF1 homolog A (HNF1A) in the regulatory mechanism of glioblastoma (GBM), the molecular mechanism, especially the downstream regulation as a transcription factor, remains to be further elucidated. Immunohistochemistry was used to detect the expression and clinical relevance of HNF1A in GBM patients. CCK8, TUNEL, and subcutaneous tumor formation in nude mice were used to evaluate the effect of HNF1A on GBM in vitro and in vivo. The correction between HNF1A and epidermal growth factor receptor pathway substrate 8 (EPS8) was illustrated by bioinformatics analysis and luciferase assay. Further mechanism was explored that the transcription factor HNF1A regulated the expression of EPS8 and downstream signaling pathways by directly binding to the promoter region of EPS8. Our comprehensive analysis of clinical samples in this study showed that upregulated expression of HNF1A was associated with poor survival in GBM patients. Further, we found that knockdown of HNF1A markedly suppressed the malignant phenotype of GBM cells in vivo and in vitro as well as promoted apoptosis of tumor cells, which was reversed by upregulation of HNF1A. Mechanistically, HNF1A could significantly activate PI3K/AKT signaling pathway by specifically binding to the promoter regions of EPS8. Moreover, overexpression of EPS8 was able to reverse the apoptosis of tumor cells caused by HNF1A knockdown, thereby exacerbating the GBM progression. Correctively, our study has clarified the explicit mechanism by which HNF1A promotes GBM malignancy and provides a new therapeutic target for further clinical application.
Collapse
Affiliation(s)
- Gang Yang
- The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, PR China; Department of Neurosurgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China
| | - Fei Su
- The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, PR China; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China
| | - Bin-Xiao Han
- Gansu Institute of Medical Information, Institute of Gansu Medical Science Research, Lanzhou, Gansu 730000, PR China
| | - Hong-Xin Su
- Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China
| | - Chen-Hao Guo
- The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, PR China; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China
| | - Shao-Hua Yu
- The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, PR China; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China
| | - Quan-Lin Guan
- The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, PR China; Department of Oncology Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China.
| | - Xiao-Ming Hou
- Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, PR China.
| |
Collapse
|
4
|
Pimiento Figueroa J, Lopera Valle JS, Gomez Urrego AM, García Gómez V, Gonzalez M, Huertas Duran C. Gadoxetic Acid in MRI: A Five-Year Experience at a High-Complexity Hospital in Colombia. Cureus 2024; 16:e58150. [PMID: 38741819 PMCID: PMC11089591 DOI: 10.7759/cureus.58150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/09/2024] [Indexed: 05/16/2024] Open
Abstract
Objective The objective of the study was to evaluate the use of the hepatospecific contrast agent, gadoxetic acid, for MRI in patients at a high-complexity hospital in Medellin, Colombia, from 2016 to 2022. Materials and methods This was an observational, descriptive, and retrospective cross-sectional study involving patients who had undergone MRI with gadoxetic acid from February 2016 to January 2022. The MRI studies were interpreted by two radiologists specializing in body imaging, each with at least 10 years of experience. The medical records of the identified patients were reviewed. Quantitative variables were presented using either means and standard deviations or medians and interquartile ranges, depending on the distribution of the variables. Qualitative variables were represented through absolute and relative frequencies. Results A total of 100 pharmacy records were collected, leading to a final sample of 75 patients aged between three and 91 years. The primary reason for imaging was to assess focal liver lesions in 58 patients (77.3%), with bile duct injury being the second most common indication in 16 patients (21.3%). A diagnostic alteration was noted in 69.3% of cases (52 patients). Among the 58 focal liver lesions analyzed using a hepatospecific agent, 31 cases (53.4%) were diagnosed as focal nodular hyperplasia. Conclusion Our study reinforces the clinical value of gadoxetic acid-enhanced MRI in refining diagnostic assessments, particularly in cases involving bile duct and focal hepatic lesions.
Collapse
Affiliation(s)
| | | | | | | | - Mateo Gonzalez
- Department of Radiology, Servicios de Salud San Vicente Fundación, Medellín, COL
| | | |
Collapse
|
5
|
Schmidt S, Sempoux C. Editorial for "Beta-Catenin-Mutated Hepatocellular Adenomas at Hepatobiliary Phase MRI: A Systematic Review and Meta-Analysis". J Magn Reson Imaging 2024. [PMID: 38426593 DOI: 10.1002/jmri.29331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Accepted: 02/20/2024] [Indexed: 03/02/2024] Open
Affiliation(s)
- Sabine Schmidt
- Department of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
| | - Christine Sempoux
- Department of Pathology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
| |
Collapse
|
6
|
Shen L, Altmayer S, Tse JR. Beta-Catenin-Mutated Hepatocellular Adenomas at Hepatobiliary Phase MRI: A Systematic Review and Meta-Analysis. J Magn Reson Imaging 2024. [PMID: 38465878 DOI: 10.1002/jmri.29279] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 03/12/2024] Open
Abstract
BACKGROUND Beta-catenin-mutated hepatocellular adenomas (β-HCAs) can appear iso- to hyperintense at the hepatobiliary phase (HBP) at magnetic resonance imaging (MRI). Given the relatively lower prevalence of β-HCAs, prior studies had limited power to show statistically significant differences in the HBP signal intensity between different subtypes. PURPOSE To assess the diagnostic performance of HBP MRI to discriminate β-HCA from other subtypes. STUDY TYPE Systemic review and meta-analysis. POPULATION Ten original studies were included, yielding 266 patients with 397 HCAs (9%, 36/397 β-HCAs and 91%, 361/397 non-β-HCAs). FIELD STRENGTH/SEQUENCE 1.5 T and 3.0 T, HBP. ASSESSMENT PubMed, Web of Science, and Embase databases were searched from January 1, 2000, to August 31, 2023, for all articles reporting HBP signal intensity in patients with histopathologically proven HCA subtypes. QUADAS-2 was used to assess risk of bias and concerns regarding applicability. STATISTICAL TESTS Univariate random-effects model was used to calculate pooled estimates. Heterogeneity estimates were assessed with I2 heterogeneity index. Meta-regression (mixed-effect model) was used to test for differences in the prevalence of HBP signal between HCA groups. The threshold for statistical significance was set at P < 0.05. RESULTS HBP iso- to hyperintensity was associated with β-HCAs (pooled prevalence was 72.3% in β-HCAs and 6.3% in non-β-HCAs). Pooled sensitivity and specificity were 72.3% (95% confidence interval 54.1-85.3) and 93.7% (93.8-97.7), respectively. Specificity had substantial heterogeneity with I2 of 83% due to one study, but not for sensitivity (I2 = 0). After excluding this study, pooled sensitivity and specificity were 77.4% (59.6-88.8) and 94.1% (88.9-96.9), with no substantial heterogeneity. One study had high risk of bias for patient selection and two studies were rated unclear for two domains. DATA CONCLUSION Iso- to hyperintensity at HBP MRI may help to distinguish β-HCA subtype from other HCAs with high specificity. However, there was heterogeneity in the pooled estimates. LEVEL OF EVIDENCE 3 TECHNICAL EFFICACY: Stage 2.
Collapse
Affiliation(s)
- Luyao Shen
- Department of Radiology, Stanford University School of Medicine, Stanford, California, USA
| | - Stephan Altmayer
- Department of Radiology, Stanford University School of Medicine, Stanford, California, USA
| | - Justin R Tse
- Department of Radiology, Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
7
|
Kim TH, Woo S. How Systematic Review Can Shape Clinical Practice in Radiology. AJR Am J Roentgenol 2024; 222:e2329603. [PMID: 37493323 DOI: 10.2214/ajr.23.29603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023]
Abstract
Systematic reviews offer radiologists a comprehensive synthesis of all relevant evidence pertaining to a specific question, aiding them in shaping their clinical practices. It is crucial for radiologists to familiarize themselves with the methods used in systematic reviews and meta-analyses and to understand the limitations. By doing so, they can effectively appraise and interpret results, enabling them to make informed decisions based on the evidence provided in systematic reviews and meta-analyses.
Collapse
Affiliation(s)
- Tae-Hyung Kim
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 29, New York, NY 10065
| | - Sungmin Woo
- Department of Radiology, NYU Langone Health, New York, NY
| |
Collapse
|
8
|
Zhang Z, Ji J, Qiu G, Hou Z, Mi S, Jin Z, Dai Y, Xie Q, Zeng Y, Huang J. Surgical indications for solid hepatic benign tumors: An updated literature review. Biosci Trends 2023; 17:325-334. [PMID: 37599079 DOI: 10.5582/bst.2023.01152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/22/2023]
Abstract
Hepatic hemangioma, focal nodular hyperplasia, and hepatic adenoma are the most common benign solid liver tumors. However, their surgical indications have been the subject of debate. Minimally invasive liver resection reduces the cost of surgery and may lead to overtreatment of benign liver tumors. Recently, there has been a growing understanding of the etiology, pathogenesis, and natural history of these tumors. Great progress has also been made in imaging. The use of MRI and contrast agents has improved the accuracy of non-invasive diagnosis of these tumors, and especially in the identification of specific molecular subtypes of liver adenoma. These factors have resulted in alterations of surgical indications for these tumors. This article examines recent literature and it discusses the surgical indications for hepatic hemangioma, focal nodular hyperplasia, and hepatic adenoma while summarizing modifications in clinical management.
Collapse
Affiliation(s)
- Zhihong Zhang
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Jun Ji
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Guoteng Qiu
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ziqi Hou
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Shizheng Mi
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Zhaoxing Jin
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yunlong Dai
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Qingyun Xie
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yong Zeng
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| | - Jiwei Huang
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
9
|
Soliman MM, Kim TH, Cheng M, McKenney AS, Fassia MK, Lamparello NA, Lee JM, Vargas HA, Woo S. Mentorship in Radiology Research: A Guide for Mentors and Mentees. Radiol Imaging Cancer 2023; 5:e230176. [PMID: 37975804 DOI: 10.1148/rycan.230176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Affiliation(s)
- Mohamed M Soliman
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Tae-Hyung Kim
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Monica Cheng
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Anna Sophia McKenney
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Mohammad-Kasim Fassia
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Nicole A Lamparello
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Jeong Min Lee
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Hebert A Vargas
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| | - Sungmin Woo
- From the Department of Radiology, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY (M.M.S., A.S.M., M.K.F., N.A.L.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (T.H.K.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (M.C.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (J.M.L.); Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea (J.M.L.); and Department of Radiology, NYU Langone Health, 660 1st Avenue, New York, NY 10016 (H.A.V., S.W.)
| |
Collapse
|
10
|
Shah R, VanSyckel A, Popescu AR, Rigsby CK, Griffin LM. Guide to use of ferumoxytol for hepatic vascular assessment as part of dual contrast MRI. Pediatr Radiol 2023; 53:2180-2187. [PMID: 37599288 DOI: 10.1007/s00247-023-05737-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 07/28/2023] [Accepted: 07/31/2023] [Indexed: 08/22/2023]
Abstract
Magnetic resonance imaging (MRI) assessment of hepatic vasculature can be challenging in the setting of liver disease and liver lesions. The widely used hepatobiliary contrast agent gadoxetate is an extracellular contrast agent that provides excellent soft tissue characterization but has limitations as a vascular contrast agent. Ferumoxytol is an iron oxide nanoparticle with superparamagnetic properties that can be used as blood pool contrast agent to provide dedicated vascular assessment. We provide a detailed protocol for evaluation of pediatric liver vasculature using ferumoxytol, after imaging of the parenchyma with gadoxetate. We provide multiple examples and discuss practical considerations when incorporating ferumoxytol into practice.
Collapse
Affiliation(s)
- Risha Shah
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Arielle VanSyckel
- Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA
| | - Andrada R Popescu
- Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA
- Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Cynthia K Rigsby
- Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA
- Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Lindsay M Griffin
- Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
- Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
| |
Collapse
|
11
|
Do RKG. Editorial Comment: An Algorithm to Distinguish Between Hepatocellular Adenoma Subtypes on Gadoxetate Disodium-Enhanced MRI. AJR Am J Roentgenol 2023; 220:549. [PMID: 36222489 DOI: 10.2214/ajr.22.28613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Richard K G Do
- Memorial Sloan Kettering Cancer Center, New York, NY , @DrRichardDo
| |
Collapse
|
12
|
Reply to "Hepatic Adenomas With Hepatobiliary Phase Iso- or Hyperintensity: Standardized Definitions Are Required". AJR Am J Roentgenol 2023; 220:456-457. [PMID: 36598414 DOI: 10.2214/ajr.22.28513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
13
|
Hepatic Adenomas With Hepatobiliary Phase Iso- or Hyperintensity: Standardized Definitions Are Required. AJR Am J Roentgenol 2023; 220:456. [PMID: 36598412 DOI: 10.2214/ajr.22.28471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
14
|
Editor's Notebook: January 2023. AJR Am J Roentgenol 2023; 220:4-5. [PMID: 36542747 DOI: 10.2214/ajr.22.28610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|